Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Bcr-Abl

Items 1-10 of 19

Page
per page
  1. AG957
    C5826 AG957
    Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
  2. PD 166326
    C3677 PD 166326
    Summary: receptor tyrosine kinases inhibitor
      ≤25 mg/mL
  3. GNF-7
    B6033 GNF-7
    Summary: Type II Bcr-Abl inhibitor
      insoluble in EtOH; insoluble in H2O; ≥5.48 mg/mL
  4. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL
  5. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  6. Bafetinib (INNO-406)
    B1011 Bafetinib (INNO-406)
     2 Citation
    Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor
      ≥57.7 mg/mL
  7. PD173955
    A8812 PD173955
    Target: Bcr-Abl|Src
    Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,
      ≥22.15 mg/mL
  8. PPY A
    A8607 PPY A
    Target: Abl kinases
    Summary: Abl kinases inhibitor
      <37.24 mg/mL
  9. PD 180970
    A8606 PD 180970
    Summary: P210bcr/abl tyrosine kinase inhibitor
      <21.46 mg/mL
  10. 1-Naphthyl PP1
    A8605 1-Naphthyl PP1
    Summary: Src family kinases inhibitor
      ≥25.32 mg/mL

Items 1-10 of 19

Page
per page